10-Q: Nu Skin Q2 Earnings Surge on Mavely Sale, Core Revenue Dips

Nu Skin Enterprises reported a significant increase in net income and EPS for Q2 2025, primarily driven by the sale of its Mavely business, despite a 12% decline in overall revenue and a drop in customer and sales force metrics.

Summary

• Revenue for the three months ended June 30, 2025, decreased by 12% to $386.1 million, compared to $439.1 million in the prior-year period.
• Revenue for the six months ended June 30, 2025, decreased by 12% to $750.6 million, compared to $856.4 million in the prior-year period.
• Net income for the second quarter of 2025 was $21.1 million, a significant improvement from a net loss of $(118.3) million in the prior-year period.
• Net income for the first six months of 2025 was $128.6 million, compared to a net loss of $(118.8) million for the first six months of 2024.
• Basic earnings per share increased to $0.43 for Q2 2025 from $(2.38) in Q2 2024, and to $2.59 for the first six months of 2025 from $(2.39) in the prior-year period.
• The company recorded a pre-tax gain of $176.2 million from the sale of its Mavely business in January 2025.
• An impairment charge of $25.1 million was recorded on the BeautyBio asset group in Q1 2025 due to a strategic shift and reduced forecasted revenues.
• Customers, Paid Affiliates, and Sales Leaders declined by 14%, 16%, and 23% respectively, on a year-over-year basis for Q2 2025.
• Cash and cash equivalents increased to $264.2 million as of June 30, 2025, from $186.9 million at the beginning of the year, driven by Mavely sale proceeds.
• Long-term debt was significantly reduced to $213.9 million as of June 30, 2025, from $363.6 million at December 31, 2024, partly due to a $115.0 million payment on the term loan facility.

Sentiment

Score: 6

Explanation: While net income and EPS showed significant improvement due to the one-time Mavely sale and debt reduction, core revenue declined across most segments, and customer/sales force metrics deteriorated. The BeautyBio impairment and unrealized investment loss are notable negatives. The future outlook for new product and market expansion is cautious for 2025, indicating ongoing operational challenges despite financial restructuring successes.

Positives

• Net income for Q2 2025 significantly improved to $21.1 million from a $(118.3) million loss in Q2 2024, and for the first six months to $128.6 million from a $(118.8) million loss.
• Basic EPS increased to $0.43 for Q2 2025 and $2.59 for the first six months of 2025, a substantial turnaround from prior-year losses.
• A pre-tax gain of $176.2 million was realized from the sale of the Mavely business.
• Long-term debt was substantially reduced by $149.7 million, from $363.6 million to $213.9 million, improving the company's financial leverage.
• Cash and cash equivalents increased by $77.3 million to $264.2 million, enhancing liquidity.
• The Manufacturing segment's revenue increased by 17.3% for Q2 2025 and 13.7% for the first half of 2025, driven by growth at the Wasatch manufacturing entity.
• Latin America markets showed strong growth, with revenue increasing by 107% year-over-year in Q2 2025, and Customers, Paid Affiliates, and Sales Leaders increasing by 112%, 52%, and 121% respectively.
• Selling expenses as a percentage of revenue decreased to 33.2% for Q2 2025 from 37.7% in the prior-year period, and to 32.9% for the first six months from 37.3%.

Negatives

• Total revenue decreased by 12% for both the three and six months ended June 30, 2025, compared to the prior-year periods.
• Customers, Paid Affiliates, and Sales Leaders declined by 14%, 16%, and 23% respectively, indicating ongoing challenges in customer acquisition and sales force engagement.
• An impairment charge of $25.1 million was recorded on the BeautyBio asset group due to a strategic shift and reduced forecasted revenues.
• A $28.1 million unrealized loss on an equity investment was recognized in the first half of 2025.
• Most geographic segments experienced revenue declines, including Southeast Asia/Pacific (-15.8%), Mainland China (-17.7%), Europe & Africa (-8.3%), South Korea (-22.8%), and Hong Kong/Taiwan (-18.7%).
• The Rhyz Other segment's revenue decreased by 70.5% in Q2 2025, primarily due to the Mavely sale and a 40% decline in BeautyBio revenue.
• Cash flow from operating activities decreased to $36.2 million for the first six months of 2025 from $54.5 million in the prior-year period.
• The introduction of sales performance plan enhancements in North America and Europe & Africa caused disruption as the sales force adapts.
• Interest expense is expected to increase after the maturity of interest rate swap arrangements on July 31, 2025.

Risks

• Continued macroeconomic challenges, including inflationary pressures and negative consumer sentiment, could negatively impact consumer spending and customer acquisition.
• Headwinds from the ongoing transformation process, including the rollout of sales performance plan enhancements, may cause further disruption to the sales force.
• Fluctuations in foreign currency exchange rates could significantly impact reported revenue and earnings, as a majority of revenue and expenses are recognized outside the U.S.
• Compliance with government regulations pertaining to product formulation, labeling, claims, advertising, and the direct selling system in numerous foreign jurisdictions poses a risk of material adverse effects if non-compliance is asserted.
• The adoption of new statutes, laws, rules, or changes in the interpretation of existing regulations could materially adversely affect operations.
• Changes to tariff and import/export regulations, and trade disputes, could increase customs expenses, impact product pricing, reduce demand, and disrupt the supply chain.
• Delays in repatriating cash from foreign subsidiaries, particularly from Mainland China and Argentina, could affect liquidity and capital allocation.
• Exposure to insider trading and market abuse laws in various jurisdictions may affect the ability of participants to accept, acquire, sell, or dispose of shares.
• Potential additional tax liabilities from regular audits by federal, state, and foreign tax authorities, and changes in tax law or rulings.
• The company's effective interest rate will increase after the maturity of interest rate swap arrangements on July 31, 2025.

Future Outlook

The company's priorities for 2025 focus on business model optimization through continued rollout of sales performance plan enhancements, a limited preview of the next connected device Prysm iO (not anticipating material revenue in 2025), and business expansion into India (nominal revenue from Q4 pre-opening, formal launch mid-2026). The company estimates capital expenditures for 2025 to be approximately $35-55 million, primarily for Rhyz plant expansion, computer systems, and facility upgrades. The effective interest rate is expected to increase after interest rate swaps mature on July 31, 2025. The company is assessing the impact of the recently enacted One Big Beautiful Bill Act (OBBBA) on its financial statements.

Management Comments

• Revenue declines for Q2 and the first six months of 2025 were largely driven by continued macroeconomic challenges impacting consumer spending and customer acquisition.
• Experienced headwinds from the transformation process despite making progress on the long-term vision.
• Not anticipating material revenue from the Prysm iO device sales in 2025 due to the timing of the limited leader preview.
• Currently anticipating nominal revenue from the fourth quarter India market pre-opening, as preparations are for a formal launch in mid-2026.
• The decrease in interest expense was primarily due to debt payments made in Q1 2025 using a portion of the proceeds from the Mavely sale.
• The effective tax rate for Q2 2025 benefited from the release of uncertain tax positions.
• Believe that existing cash balances, future cash flows from operations, and existing lines of credit will be adequate to fund cash needs on both a shortand long-term basis.
• Stock repurchases are used primarily to offset dilution from equity incentive plans and for strategic initiatives.
• The continued declaration of dividends is subject to the discretion of the board of directors and will depend upon various factors, including net earnings, financial condition, cash requirements, future prospects, and other relevant factors.

Industry Context

The company's performance reflects broader industry trends of macroeconomic challenges, including inflationary pressures and decreased consumer spending, which are negatively impacting customer acquisition and sales force engagement in the direct selling and beauty/wellness sectors. The decline in Mainland China also highlights a negative sentiment towards U.S. brands in that market. The company's strategic shifts, such as optimizing business models and expanding into new markets like India, are common responses to these challenging market conditions, aiming to diversify revenue streams and adapt to evolving consumer behaviors.

Comparison to Industry Standards

• No specific comparable companies, projects, or global benchmarks were mentioned in the filing to assess the results in the context of industry standards.

Corporate Governance

Legal Proceedings

• The company and its subsidiaries are defendants in litigation, investigations, and other proceedings arising in the ordinary course of business. Management believes ultimate liability is not likely to have a material adverse effect.

Stakeholder Impact

• Shareholders: Benefited from increased net income and EPS due to the Mavely sale, continued quarterly cash dividends of $0.06 per share, and ongoing stock repurchase program. However, core revenue declines and sales force contraction may raise concerns about long-term organic growth.
• Employees: Impacted by workforce reductions as part of the 2023 restructuring plan, which included severance charges.
• Customers: Experienced negative impacts from macroeconomic challenges, leading to decreased consumer spending and a 14% decline in customer numbers.
• Sales Force (Paid Affiliates & Sales Leaders): Faced disruption from sales performance plan enhancements and macroeconomic headwinds, resulting in 16% fewer Paid Affiliates and 23% fewer Sales Leaders.
• Creditors: Benefited from significant debt reduction, improving the company's credit profile and compliance with debt covenants.

Next Steps

• Continue the rollout of enhancements to the sales performance plan.
• Conduct a limited preview of the next connected device, Prysm iO.
• Prepare for the pre-opening of the India market in Q4 2025, with a formal launch in mid-2026.
• Make remaining payments under the 2023 restructuring plan in the back half of 2025.
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.
• Monitor macroeconomic trends and uncertainties related to international trade relations and trade policy, including tariffs.

Key Dates

Recommendation

While Nu Skin's Q2 2025 results show a significant improvement in net income and EPS, primarily driven by the one-time gain from the Mavely business sale and substantial debt reduction, the underlying operational performance remains challenged. Core revenue declined across most segments, and key metrics like customers, paid affiliates, and sales leaders saw double-digit percentage drops. Macroeconomic headwinds and disruption from internal transformation initiatives are ongoing concerns. The positive financial restructuring is offset by a lack of clear organic growth momentum. Investors should hold, awaiting clearer signs of sustainable revenue growth and successful execution of strategic initiatives like the Prysm iO launch and India expansion, which are not expected to materially impact 2025 results.

Keywords

Nu Skin, NUS, SEC Filing, 10-Q, Quarterly Report, Financial Results, Revenue, Net Income, EPS, Mavely Sale, BeautyBio Impairment, Restructuring, Debt Reduction, Direct Selling, Beauty Products, Wellness Products, Global Markets, Sales Leaders, Customer Acquisition, Macroeconomic Factors, Capital Expenditures, Dividends, Stock Repurchase, Foreign Currency Risk, Taxation